Transcriptome Profiling Identifies TIGIT as a Marker of T‐Cell Exhaustion in Liver Cancer
BACKGROUND AND AIMS Programmed death 1 (PD‐1) checkpoint inhibition has shown promising results in patients with hepatocellular carcinoma, inducing objective responses in approximately 20% of treated patients. The roles of other coinhibitory molecules and their individual contributions to T‐cell dys...
Gespeichert in:
Veröffentlicht in: | Hepatology (Baltimore, Md.) Md.), 2021-04, Vol.73 (4), p.1399-1418 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1418 |
---|---|
container_issue | 4 |
container_start_page | 1399 |
container_title | Hepatology (Baltimore, Md.) |
container_volume | 73 |
creator | Ostroumov, Dmitrij Duong, Steven Wingerath, Jessica Woller, Norman Manns, Michael P. Timrott, Kai Kleine, Moritz Ramackers, Wolf Roessler, Stephanie Nahnsen, Sven immunoglobulin and immunoreceptor tyrosiCzemmel Dittrich‐Breiholz, Oliver Eggert, Tobias Kühnel, Florian Wirth, Thomas C. |
description | BACKGROUND AND AIMS
Programmed death 1 (PD‐1) checkpoint inhibition has shown promising results in patients with hepatocellular carcinoma, inducing objective responses in approximately 20% of treated patients. The roles of other coinhibitory molecules and their individual contributions to T‐cell dysfunction in liver cancer, however, remain largely elusive.
APPROACH AND RESULTS
We performed a comprehensive mRNA profiling of cluster of differentiation 8 (CD8) T cells in a murine model of autochthonous liver cancer by comparing the transcriptome of naive, functional effector, and exhausted, tumor‐specific CD8 T cells. Subsequently, we functionally validated the role of identified genes in T‐cell exhaustion. Our results reveal a unique transcriptome signature of exhausted T cells and demonstrate that up‐regulation of the inhibitory immune receptor T‐cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine‐based inhibitor motif domains (TIGIT) represents a hallmark in the process of T‐cell exhaustion in liver cancer. Compared to PD‐1, expression of TIGIT more reliably identified exhausted CD8 T cells at different stages of their differentiation. In combination with PD‐1 inhibition, targeting of TIGIT with antagonistic antibodies resulted in synergistic inhibition of liver cancer growth in immunocompetent mice. Finally, we demonstrate expression of TIGIT on tumor‐infiltrating CD8 T cells in tissue samples of patients with hepatocellular carcinoma and intrahepatic cholangiocarcinoma and identify two subsets of patients based on differential expression of TIGIT on tumor‐specific T cells.
CONCLUSIONS
Our transcriptome analysis provides a valuable resource for the identification of key pathways involved in T‐cell exhaustion in patients with liver cancer and identifies TIGIT as a potential target in checkpoint combination therapies. |
doi_str_mv | 10.1002/hep.31466 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2427524010</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2512167671</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4286-b315741f44eaeabec0f8d081e761dfaaf5e10866a8e12580a395ccdcc185b00f3</originalsourceid><addsrcrecordid>eNp1kMGO0zAQhi0EYkvhwAsgS1zgkHbGiZ3kiKrubqUieggnDpbrjFmXNCl2A-xtH4Fn5EnWSwsHJE5zmE-ffn2MvUSYIYCY39BhlmOh1CM2QSnKLM8lPGYTECVkNeb1BXsW4w4A6kJUT9lFLkpUUtYT9qkJpo82-MNx2BPfhMH5zvef-aql_uidp8ib1dWq4SZyw9-b8IUCHxxvft39XFDX8eWPGzPGox967nu-9t_Sf2F6S-E5e-JMF-nF-U7Zx8tls7jO1h-uVot368ymNSrb5ijLAl1RkCGzJQuuaqFCKhW2zhgnCaFSylSEQlZg8lpa21qLldwCuHzK3py8hzB8HSke9d5Hm7aZnoYxalGIUooCEBL6-h90N4yhT-u0kChQlarERL09UTYMMQZy-hD83oRbjaAfiutUXP8unthXZ-O43VP7l_yTOAHzE_Ddd3T7f5O-Xm5Oynt2JInU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2512167671</pqid></control><display><type>article</type><title>Transcriptome Profiling Identifies TIGIT as a Marker of T‐Cell Exhaustion in Liver Cancer</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Ostroumov, Dmitrij ; Duong, Steven ; Wingerath, Jessica ; Woller, Norman ; Manns, Michael P. ; Timrott, Kai ; Kleine, Moritz ; Ramackers, Wolf ; Roessler, Stephanie ; Nahnsen, Sven ; immunoglobulin and immunoreceptor tyrosiCzemmel ; Dittrich‐Breiholz, Oliver ; Eggert, Tobias ; Kühnel, Florian ; Wirth, Thomas C.</creator><creatorcontrib>Ostroumov, Dmitrij ; Duong, Steven ; Wingerath, Jessica ; Woller, Norman ; Manns, Michael P. ; Timrott, Kai ; Kleine, Moritz ; Ramackers, Wolf ; Roessler, Stephanie ; Nahnsen, Sven ; immunoglobulin and immunoreceptor tyrosiCzemmel ; Dittrich‐Breiholz, Oliver ; Eggert, Tobias ; Kühnel, Florian ; Wirth, Thomas C.</creatorcontrib><description>BACKGROUND AND AIMS
Programmed death 1 (PD‐1) checkpoint inhibition has shown promising results in patients with hepatocellular carcinoma, inducing objective responses in approximately 20% of treated patients. The roles of other coinhibitory molecules and their individual contributions to T‐cell dysfunction in liver cancer, however, remain largely elusive.
APPROACH AND RESULTS
We performed a comprehensive mRNA profiling of cluster of differentiation 8 (CD8) T cells in a murine model of autochthonous liver cancer by comparing the transcriptome of naive, functional effector, and exhausted, tumor‐specific CD8 T cells. Subsequently, we functionally validated the role of identified genes in T‐cell exhaustion. Our results reveal a unique transcriptome signature of exhausted T cells and demonstrate that up‐regulation of the inhibitory immune receptor T‐cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine‐based inhibitor motif domains (TIGIT) represents a hallmark in the process of T‐cell exhaustion in liver cancer. Compared to PD‐1, expression of TIGIT more reliably identified exhausted CD8 T cells at different stages of their differentiation. In combination with PD‐1 inhibition, targeting of TIGIT with antagonistic antibodies resulted in synergistic inhibition of liver cancer growth in immunocompetent mice. Finally, we demonstrate expression of TIGIT on tumor‐infiltrating CD8 T cells in tissue samples of patients with hepatocellular carcinoma and intrahepatic cholangiocarcinoma and identify two subsets of patients based on differential expression of TIGIT on tumor‐specific T cells.
CONCLUSIONS
Our transcriptome analysis provides a valuable resource for the identification of key pathways involved in T‐cell exhaustion in patients with liver cancer and identifies TIGIT as a potential target in checkpoint combination therapies.</description><identifier>ISSN: 0270-9139</identifier><identifier>EISSN: 1527-3350</identifier><identifier>DOI: 10.1002/hep.31466</identifier><identifier>PMID: 32716559</identifier><language>eng</language><publisher>United States: Wolters Kluwer Health, Inc</publisher><subject>Aged ; Animal models ; Animals ; Apoptosis ; Bile Duct Neoplasms - genetics ; Bile Duct Neoplasms - immunology ; Bile Duct Neoplasms - pathology ; Biomarkers, Tumor - genetics ; Carcinoma, Hepatocellular - drug therapy ; Carcinoma, Hepatocellular - genetics ; Carcinoma, Hepatocellular - immunology ; Carcinoma, Hepatocellular - pathology ; CD8 antigen ; CD8-Positive T-Lymphocytes - immunology ; Cell differentiation ; Cell Line, Tumor ; Cholangiocarcinoma ; Cholangiocarcinoma - genetics ; Cholangiocarcinoma - immunology ; Cholangiocarcinoma - pathology ; Disease Models, Animal ; Drug Therapy, Combination ; Female ; Gene expression ; Gene Expression Profiling - methods ; Hepatocellular carcinoma ; Hepatocytes ; Hepatology ; Humans ; Immune Checkpoint Inhibitors - therapeutic use ; Liver cancer ; Liver diseases ; Liver Neoplasms - drug therapy ; Liver Neoplasms - genetics ; Liver Neoplasms - immunology ; Liver Neoplasms - pathology ; Lymphocytes ; Lymphocytes T ; Lymphocytes, Tumor-Infiltrating - immunology ; Male ; Mice ; Mice, Inbred C57BL ; Middle Aged ; PD-1 protein ; Programmed Cell Death 1 Receptor - antagonists & inhibitors ; Receptors, Immunologic - antagonists & inhibitors ; Receptors, Immunologic - genetics ; Transcriptome ; Transcriptomes ; Treatment Outcome ; Tumor Burden - drug effects ; Tyrosine</subject><ispartof>Hepatology (Baltimore, Md.), 2021-04, Vol.73 (4), p.1399-1418</ispartof><rights>2020 The Authors. Hepatology published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases.</rights><rights>2020. This article is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4286-b315741f44eaeabec0f8d081e761dfaaf5e10866a8e12580a395ccdcc185b00f3</citedby><cites>FETCH-LOGICAL-c4286-b315741f44eaeabec0f8d081e761dfaaf5e10866a8e12580a395ccdcc185b00f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fhep.31466$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fhep.31466$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32716559$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ostroumov, Dmitrij</creatorcontrib><creatorcontrib>Duong, Steven</creatorcontrib><creatorcontrib>Wingerath, Jessica</creatorcontrib><creatorcontrib>Woller, Norman</creatorcontrib><creatorcontrib>Manns, Michael P.</creatorcontrib><creatorcontrib>Timrott, Kai</creatorcontrib><creatorcontrib>Kleine, Moritz</creatorcontrib><creatorcontrib>Ramackers, Wolf</creatorcontrib><creatorcontrib>Roessler, Stephanie</creatorcontrib><creatorcontrib>Nahnsen, Sven</creatorcontrib><creatorcontrib>immunoglobulin and immunoreceptor tyrosiCzemmel</creatorcontrib><creatorcontrib>Dittrich‐Breiholz, Oliver</creatorcontrib><creatorcontrib>Eggert, Tobias</creatorcontrib><creatorcontrib>Kühnel, Florian</creatorcontrib><creatorcontrib>Wirth, Thomas C.</creatorcontrib><title>Transcriptome Profiling Identifies TIGIT as a Marker of T‐Cell Exhaustion in Liver Cancer</title><title>Hepatology (Baltimore, Md.)</title><addtitle>Hepatology</addtitle><description>BACKGROUND AND AIMS
Programmed death 1 (PD‐1) checkpoint inhibition has shown promising results in patients with hepatocellular carcinoma, inducing objective responses in approximately 20% of treated patients. The roles of other coinhibitory molecules and their individual contributions to T‐cell dysfunction in liver cancer, however, remain largely elusive.
APPROACH AND RESULTS
We performed a comprehensive mRNA profiling of cluster of differentiation 8 (CD8) T cells in a murine model of autochthonous liver cancer by comparing the transcriptome of naive, functional effector, and exhausted, tumor‐specific CD8 T cells. Subsequently, we functionally validated the role of identified genes in T‐cell exhaustion. Our results reveal a unique transcriptome signature of exhausted T cells and demonstrate that up‐regulation of the inhibitory immune receptor T‐cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine‐based inhibitor motif domains (TIGIT) represents a hallmark in the process of T‐cell exhaustion in liver cancer. Compared to PD‐1, expression of TIGIT more reliably identified exhausted CD8 T cells at different stages of their differentiation. In combination with PD‐1 inhibition, targeting of TIGIT with antagonistic antibodies resulted in synergistic inhibition of liver cancer growth in immunocompetent mice. Finally, we demonstrate expression of TIGIT on tumor‐infiltrating CD8 T cells in tissue samples of patients with hepatocellular carcinoma and intrahepatic cholangiocarcinoma and identify two subsets of patients based on differential expression of TIGIT on tumor‐specific T cells.
CONCLUSIONS
Our transcriptome analysis provides a valuable resource for the identification of key pathways involved in T‐cell exhaustion in patients with liver cancer and identifies TIGIT as a potential target in checkpoint combination therapies.</description><subject>Aged</subject><subject>Animal models</subject><subject>Animals</subject><subject>Apoptosis</subject><subject>Bile Duct Neoplasms - genetics</subject><subject>Bile Duct Neoplasms - immunology</subject><subject>Bile Duct Neoplasms - pathology</subject><subject>Biomarkers, Tumor - genetics</subject><subject>Carcinoma, Hepatocellular - drug therapy</subject><subject>Carcinoma, Hepatocellular - genetics</subject><subject>Carcinoma, Hepatocellular - immunology</subject><subject>Carcinoma, Hepatocellular - pathology</subject><subject>CD8 antigen</subject><subject>CD8-Positive T-Lymphocytes - immunology</subject><subject>Cell differentiation</subject><subject>Cell Line, Tumor</subject><subject>Cholangiocarcinoma</subject><subject>Cholangiocarcinoma - genetics</subject><subject>Cholangiocarcinoma - immunology</subject><subject>Cholangiocarcinoma - pathology</subject><subject>Disease Models, Animal</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Gene expression</subject><subject>Gene Expression Profiling - methods</subject><subject>Hepatocellular carcinoma</subject><subject>Hepatocytes</subject><subject>Hepatology</subject><subject>Humans</subject><subject>Immune Checkpoint Inhibitors - therapeutic use</subject><subject>Liver cancer</subject><subject>Liver diseases</subject><subject>Liver Neoplasms - drug therapy</subject><subject>Liver Neoplasms - genetics</subject><subject>Liver Neoplasms - immunology</subject><subject>Liver Neoplasms - pathology</subject><subject>Lymphocytes</subject><subject>Lymphocytes T</subject><subject>Lymphocytes, Tumor-Infiltrating - immunology</subject><subject>Male</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Middle Aged</subject><subject>PD-1 protein</subject><subject>Programmed Cell Death 1 Receptor - antagonists & inhibitors</subject><subject>Receptors, Immunologic - antagonists & inhibitors</subject><subject>Receptors, Immunologic - genetics</subject><subject>Transcriptome</subject><subject>Transcriptomes</subject><subject>Treatment Outcome</subject><subject>Tumor Burden - drug effects</subject><subject>Tyrosine</subject><issn>0270-9139</issn><issn>1527-3350</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>EIF</sourceid><recordid>eNp1kMGO0zAQhi0EYkvhwAsgS1zgkHbGiZ3kiKrubqUieggnDpbrjFmXNCl2A-xtH4Fn5EnWSwsHJE5zmE-ffn2MvUSYIYCY39BhlmOh1CM2QSnKLM8lPGYTECVkNeb1BXsW4w4A6kJUT9lFLkpUUtYT9qkJpo82-MNx2BPfhMH5zvef-aql_uidp8ib1dWq4SZyw9-b8IUCHxxvft39XFDX8eWPGzPGox967nu-9t_Sf2F6S-E5e-JMF-nF-U7Zx8tls7jO1h-uVot368ymNSrb5ijLAl1RkCGzJQuuaqFCKhW2zhgnCaFSylSEQlZg8lpa21qLldwCuHzK3py8hzB8HSke9d5Hm7aZnoYxalGIUooCEBL6-h90N4yhT-u0kChQlarERL09UTYMMQZy-hD83oRbjaAfiutUXP8unthXZ-O43VP7l_yTOAHzE_Ddd3T7f5O-Xm5Oynt2JInU</recordid><startdate>202104</startdate><enddate>202104</enddate><creator>Ostroumov, Dmitrij</creator><creator>Duong, Steven</creator><creator>Wingerath, Jessica</creator><creator>Woller, Norman</creator><creator>Manns, Michael P.</creator><creator>Timrott, Kai</creator><creator>Kleine, Moritz</creator><creator>Ramackers, Wolf</creator><creator>Roessler, Stephanie</creator><creator>Nahnsen, Sven</creator><creator>immunoglobulin and immunoreceptor tyrosiCzemmel</creator><creator>Dittrich‐Breiholz, Oliver</creator><creator>Eggert, Tobias</creator><creator>Kühnel, Florian</creator><creator>Wirth, Thomas C.</creator><general>Wolters Kluwer Health, Inc</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>202104</creationdate><title>Transcriptome Profiling Identifies TIGIT as a Marker of T‐Cell Exhaustion in Liver Cancer</title><author>Ostroumov, Dmitrij ; Duong, Steven ; Wingerath, Jessica ; Woller, Norman ; Manns, Michael P. ; Timrott, Kai ; Kleine, Moritz ; Ramackers, Wolf ; Roessler, Stephanie ; Nahnsen, Sven ; immunoglobulin and immunoreceptor tyrosiCzemmel ; Dittrich‐Breiholz, Oliver ; Eggert, Tobias ; Kühnel, Florian ; Wirth, Thomas C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4286-b315741f44eaeabec0f8d081e761dfaaf5e10866a8e12580a395ccdcc185b00f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Aged</topic><topic>Animal models</topic><topic>Animals</topic><topic>Apoptosis</topic><topic>Bile Duct Neoplasms - genetics</topic><topic>Bile Duct Neoplasms - immunology</topic><topic>Bile Duct Neoplasms - pathology</topic><topic>Biomarkers, Tumor - genetics</topic><topic>Carcinoma, Hepatocellular - drug therapy</topic><topic>Carcinoma, Hepatocellular - genetics</topic><topic>Carcinoma, Hepatocellular - immunology</topic><topic>Carcinoma, Hepatocellular - pathology</topic><topic>CD8 antigen</topic><topic>CD8-Positive T-Lymphocytes - immunology</topic><topic>Cell differentiation</topic><topic>Cell Line, Tumor</topic><topic>Cholangiocarcinoma</topic><topic>Cholangiocarcinoma - genetics</topic><topic>Cholangiocarcinoma - immunology</topic><topic>Cholangiocarcinoma - pathology</topic><topic>Disease Models, Animal</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Gene expression</topic><topic>Gene Expression Profiling - methods</topic><topic>Hepatocellular carcinoma</topic><topic>Hepatocytes</topic><topic>Hepatology</topic><topic>Humans</topic><topic>Immune Checkpoint Inhibitors - therapeutic use</topic><topic>Liver cancer</topic><topic>Liver diseases</topic><topic>Liver Neoplasms - drug therapy</topic><topic>Liver Neoplasms - genetics</topic><topic>Liver Neoplasms - immunology</topic><topic>Liver Neoplasms - pathology</topic><topic>Lymphocytes</topic><topic>Lymphocytes T</topic><topic>Lymphocytes, Tumor-Infiltrating - immunology</topic><topic>Male</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Middle Aged</topic><topic>PD-1 protein</topic><topic>Programmed Cell Death 1 Receptor - antagonists & inhibitors</topic><topic>Receptors, Immunologic - antagonists & inhibitors</topic><topic>Receptors, Immunologic - genetics</topic><topic>Transcriptome</topic><topic>Transcriptomes</topic><topic>Treatment Outcome</topic><topic>Tumor Burden - drug effects</topic><topic>Tyrosine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ostroumov, Dmitrij</creatorcontrib><creatorcontrib>Duong, Steven</creatorcontrib><creatorcontrib>Wingerath, Jessica</creatorcontrib><creatorcontrib>Woller, Norman</creatorcontrib><creatorcontrib>Manns, Michael P.</creatorcontrib><creatorcontrib>Timrott, Kai</creatorcontrib><creatorcontrib>Kleine, Moritz</creatorcontrib><creatorcontrib>Ramackers, Wolf</creatorcontrib><creatorcontrib>Roessler, Stephanie</creatorcontrib><creatorcontrib>Nahnsen, Sven</creatorcontrib><creatorcontrib>immunoglobulin and immunoreceptor tyrosiCzemmel</creatorcontrib><creatorcontrib>Dittrich‐Breiholz, Oliver</creatorcontrib><creatorcontrib>Eggert, Tobias</creatorcontrib><creatorcontrib>Kühnel, Florian</creatorcontrib><creatorcontrib>Wirth, Thomas C.</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Wiley Online Library Free Content</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Hepatology (Baltimore, Md.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ostroumov, Dmitrij</au><au>Duong, Steven</au><au>Wingerath, Jessica</au><au>Woller, Norman</au><au>Manns, Michael P.</au><au>Timrott, Kai</au><au>Kleine, Moritz</au><au>Ramackers, Wolf</au><au>Roessler, Stephanie</au><au>Nahnsen, Sven</au><au>immunoglobulin and immunoreceptor tyrosiCzemmel</au><au>Dittrich‐Breiholz, Oliver</au><au>Eggert, Tobias</au><au>Kühnel, Florian</au><au>Wirth, Thomas C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Transcriptome Profiling Identifies TIGIT as a Marker of T‐Cell Exhaustion in Liver Cancer</atitle><jtitle>Hepatology (Baltimore, Md.)</jtitle><addtitle>Hepatology</addtitle><date>2021-04</date><risdate>2021</risdate><volume>73</volume><issue>4</issue><spage>1399</spage><epage>1418</epage><pages>1399-1418</pages><issn>0270-9139</issn><eissn>1527-3350</eissn><abstract>BACKGROUND AND AIMS
Programmed death 1 (PD‐1) checkpoint inhibition has shown promising results in patients with hepatocellular carcinoma, inducing objective responses in approximately 20% of treated patients. The roles of other coinhibitory molecules and their individual contributions to T‐cell dysfunction in liver cancer, however, remain largely elusive.
APPROACH AND RESULTS
We performed a comprehensive mRNA profiling of cluster of differentiation 8 (CD8) T cells in a murine model of autochthonous liver cancer by comparing the transcriptome of naive, functional effector, and exhausted, tumor‐specific CD8 T cells. Subsequently, we functionally validated the role of identified genes in T‐cell exhaustion. Our results reveal a unique transcriptome signature of exhausted T cells and demonstrate that up‐regulation of the inhibitory immune receptor T‐cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine‐based inhibitor motif domains (TIGIT) represents a hallmark in the process of T‐cell exhaustion in liver cancer. Compared to PD‐1, expression of TIGIT more reliably identified exhausted CD8 T cells at different stages of their differentiation. In combination with PD‐1 inhibition, targeting of TIGIT with antagonistic antibodies resulted in synergistic inhibition of liver cancer growth in immunocompetent mice. Finally, we demonstrate expression of TIGIT on tumor‐infiltrating CD8 T cells in tissue samples of patients with hepatocellular carcinoma and intrahepatic cholangiocarcinoma and identify two subsets of patients based on differential expression of TIGIT on tumor‐specific T cells.
CONCLUSIONS
Our transcriptome analysis provides a valuable resource for the identification of key pathways involved in T‐cell exhaustion in patients with liver cancer and identifies TIGIT as a potential target in checkpoint combination therapies.</abstract><cop>United States</cop><pub>Wolters Kluwer Health, Inc</pub><pmid>32716559</pmid><doi>10.1002/hep.31466</doi><tpages>20</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0270-9139 |
ispartof | Hepatology (Baltimore, Md.), 2021-04, Vol.73 (4), p.1399-1418 |
issn | 0270-9139 1527-3350 |
language | eng |
recordid | cdi_proquest_miscellaneous_2427524010 |
source | MEDLINE; Wiley Online Library Journals Frontfile Complete; EZB-FREE-00999 freely available EZB journals |
subjects | Aged Animal models Animals Apoptosis Bile Duct Neoplasms - genetics Bile Duct Neoplasms - immunology Bile Duct Neoplasms - pathology Biomarkers, Tumor - genetics Carcinoma, Hepatocellular - drug therapy Carcinoma, Hepatocellular - genetics Carcinoma, Hepatocellular - immunology Carcinoma, Hepatocellular - pathology CD8 antigen CD8-Positive T-Lymphocytes - immunology Cell differentiation Cell Line, Tumor Cholangiocarcinoma Cholangiocarcinoma - genetics Cholangiocarcinoma - immunology Cholangiocarcinoma - pathology Disease Models, Animal Drug Therapy, Combination Female Gene expression Gene Expression Profiling - methods Hepatocellular carcinoma Hepatocytes Hepatology Humans Immune Checkpoint Inhibitors - therapeutic use Liver cancer Liver diseases Liver Neoplasms - drug therapy Liver Neoplasms - genetics Liver Neoplasms - immunology Liver Neoplasms - pathology Lymphocytes Lymphocytes T Lymphocytes, Tumor-Infiltrating - immunology Male Mice Mice, Inbred C57BL Middle Aged PD-1 protein Programmed Cell Death 1 Receptor - antagonists & inhibitors Receptors, Immunologic - antagonists & inhibitors Receptors, Immunologic - genetics Transcriptome Transcriptomes Treatment Outcome Tumor Burden - drug effects Tyrosine |
title | Transcriptome Profiling Identifies TIGIT as a Marker of T‐Cell Exhaustion in Liver Cancer |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T20%3A59%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Transcriptome%20Profiling%20Identifies%20TIGIT%20as%20a%20Marker%20of%20T%E2%80%90Cell%20Exhaustion%20in%20Liver%20Cancer&rft.jtitle=Hepatology%20(Baltimore,%20Md.)&rft.au=Ostroumov,%20Dmitrij&rft.date=2021-04&rft.volume=73&rft.issue=4&rft.spage=1399&rft.epage=1418&rft.pages=1399-1418&rft.issn=0270-9139&rft.eissn=1527-3350&rft_id=info:doi/10.1002/hep.31466&rft_dat=%3Cproquest_cross%3E2512167671%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2512167671&rft_id=info:pmid/32716559&rfr_iscdi=true |